Imagion Biosystems Limited

Equities

IBX

AU000000IBX6

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. Other stock markets 01:14:11 2024-07-03 am EDT			5-day change	1st Jan Change
0.082 ^AUD	-2.38%		0.00%	-76.90%

Jul. 02	Imagion Biosystems Limited Announces Change of Registered Office & Principal Place of Business	CI
Feb. 29	Imagion Biosystems Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Imagion Biosystems Limited Announces Change of Registered Office & Principal Place of Business

July 01, 2024 at 06:59 pm EDT

Imagion Biosystems Limited announced that effective from 1 July 2024, the Registered Office and Principal Place of Business will change to: Registered Office and Principal Place of Business: Address: Level 4, 96-100 Albert Road, South Melbourne VIC 3205.

Latest news about Imagion Biosystems Limited

Imagion Biosystems Limited Announces Change of Registered Office & Principal Place of Business	Jul. 01	CI
Imagion Biosystems Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Imagion Biosystems CEO Resigns	Jan. 15	MT
Imagion Biosystems Limited Informs Chairman Bob Proulx to Resume Operating Responsibilities as Interim Executive Chair	Jan. 14	CI
Imagion Biosystems Limited Announces Departure of Isaac Bright as CEO	Jan. 14	CI
Imagion Biosystems Validates Safety, Feasibility of Breast Cancer Imaging Agent in Phase One Trial; Shares Rise 7%	Dec. 06	MT
Argenica Therapeutics Appoints Nonexecutive Chair	Nov. 29	MT
Imagion Biosystems Limited Approves Election of Isaac Bright as Director	Nov. 12	CI
Imagion Biosystems Completes Phase 1 Imaging Agent Study	23-10-18	MT
Imagion Biosystems Limited Announces Update on Magsense Her2 Program	23-10-01	CI
Imagion Biosystems Secures AU$3.5 Million R&D Tax Rebate for Fiscal Year 2022	23-09-19	MT
Imagion Biosystems Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29	CI
Imagion Biosystems Limited Appoints Robert Proulx as Non-Executive Chairman	23-07-16	CI
Imagion Biosystems Limited Announces Executive Changes	23-07-16	CI
Easing Inflation Boosts Australian Shares	23-06-28	MT
Imagion Biosystems, Siemens Healthineers Expand US Collaboration; Shares Jump 33%	23-06-27	MT
Imagion Biosystems Completes Enrollment for Imaging Agent Trial; Shares Surge 25%	23-06-21	MT
Imagion Biosystems Appoints CEO	23-06-18	MT
Imagion Biosystems Limited Announces CEO Changes	23-06-18	CI
Imagion Biosystems Limited Announces Resignation of Bob Proulx as CEO	23-04-27	CI
Imagion Biosystems Raises AU$412,903 Via Entitlement Offer; Shares Slip 6%	23-04-19	MT
Imagion Biosystems Sets Timeline for Application Filing of US Phase 2 Study of Breast Cancer Imaging Agent	23-03-27	MT
Imagion Biosystems Limited Provides an Update on Development Plans for Its MagSense HER2 imaging agent	23-03-26	CI
Imagion Biosystems Limited announced that it expects to receive AUD 15 million in funding from Mercer Street Capital Partners, LLC	23-03-06	CI
Imagion Biosystems Secures Second Grant Funding for Prostate Cancer Imaging Technology	23-03-01	MT

Chart Imagion Biosystems Limited

Duration

Period

More charts

Company Profile

Imagion Biosystems Limited is a medical imaging company engaged in developing medical imaging technologies for various cancer types. The Company uses bio-safe magnetic nanoparticles to detect cancer and other diseases. Its principal activity consists of nanotechnology, biotechnology, cancer diagnostics and medical imaging using magnetic resonance. The Company operates through Research and Development segment. It is advancing clinical development of its MagSense platform technology to revolutionize cancer diagnosis, introducing molecular imaging to Magnetic resonance imaging (MRI). The Companyâs lead program has demonstrated its technology embodied in MagSense HER2 Imaging Agent (MSH2IA) is safe and well-tolerated in patients diagnosed with HER2+ breast cancer. Its MagSense pipeline includes prostate cancer, ovarian cancer, pancreatic cancer, and brain cancer programs. Its PrecisionMRX products include Dextran-Coated, mPEG Coated, Oleic Acid Coated and Carboxylic Acid Functionalized.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-08-27 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Medical Diagnostic & Testing Equipment

	1st Jan change	Capi.
IMAGION BIOSYSTEMS LIMITED	-76.90%	1.83M
SARTORIUS AG	-35.14%	14.31B
QUIDELORTHO CORPORATION	-57.45%	2.1B
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	+23.88%	1.95B
SHANGHAI MICROPORT EP MEDTECH CO., LTD.	-22.96%	1.28B
BIOTAGE AB	+19.52%	1.21B
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.	-34.82%	748M
REVENIO GROUP OYJ	+1.25%	779M
CONTEC MEDICAL SYSTEMS CO.,LTD	-36.84%	720M
VAREX IMAGING CORPORATION	-28.88%	596M

Medical Diagnostic & Testing Equipment